迪瑞医疗：预计2025年亏损1.8亿元-3.5亿元

Core Viewpoint - The company, Dirui Medical (300396), has announced a significant expected loss for the year 2025, projecting a net loss attributable to shareholders between 180 million to 350 million yuan, compared to a profit of 142 million yuan in the previous year [4]. Financial Performance - The expected net profit for 2025 is projected to be a loss of 1.8 billion to 3.5 billion yuan, with a non-recurring net profit loss estimated between 1.85 billion to 3.6 billion yuan, compared to a profit of 1.34 billion yuan in the previous year [4]. - The company's price-to-book ratio (LF) is approximately 1.91 times, and the price-to-sales ratio (TTM) is about 7.1 times based on the latest closing price [4]. Market Challenges - The anticipated shift from profit to loss is attributed to intensified market competition, asset impairment, and several operational challenges, particularly in the domestic market [13]. - Key factors impacting revenue include underperformance in the output of instrument products and reagents, adjustments in product pricing affecting gross margins, increased marketing expenditures, and higher credit and asset impairment losses compared to the previous year [13]. Historical Financial Trends - Historical net profit and non-recurring profit data indicate a downward trend, with the company experiencing a significant decline in profitability from previous years [14]. - The year-on-year growth rates for net profit and non-recurring net profit have shown negative trends, with a notable decrease of 286.72% projected for 2025 [14].